Immunologically Defined Prognostic Subgroups as Predictors of Response to BCG Immunotherapy
Fifty-two stage I and II patients with nonsmall cell lung cancer were randomized after resection to no further therapy, BCG, or BCG plus allogeneic tumor cells. Patients have been observed for 16—65 months (mean 39.5). When the two immunotherapy arms were combined and plotted against controls, trend analysis suggested (P = 0.088) an increase in disease-free interval (DFI) only for stage I patients. The one-way mixed lymphocyte culture (MLC) values were depressed in some patients prior to any immune stimulation. Immunotherapy significantly benefited DFI among patients with a depressed MLC.
KeywordsLung Cancer Patient Disease Free Interval Mixed Lymphocyte Culture Lymphoproliferative Response Prognostic Subgroup
Unable to display preview. Download preview PDF.
- 3.Cannon GB, Weese JL, Oldham RK, Herberman RB, Dean JH, McCoy JL (1978) Lymphocyte proliferation responses of patients with carcinoma of the breast or lung to mitogens, alloantigens, and tumor-associated antigens. In: Nieburgs HE (ed) Proceedings of third international symposium for detection and prevention of cancer, vol 1. Mt. Sinai School of Medicine, City University of New York. New York, pp 425–446Google Scholar
- 10.Reid JW, Perlin E, Oldham RK, Weese JL, Heim W, Mills M, Miller C, Blom J, Green D, Ballinger S, Cannon BG, Law I, Connor R, Herberman RB (to be published) Immunotherapy of carcinoma of the lung with intradermal BCG and allogeneic tumor cells: A clinical trial. Elsevier North-Holland, New YorkGoogle Scholar